Gregory Zante
Vermögen: 6 Mio $ am 31.05.2026
Vermögen: 6 Mio $ am 31.05.2026
Gregory S.
Zante is Chief Financial & Accounting Officer at Viking Therapeutics, Inc. since 2021.
Formerly, Mr. Zante was Chief Financial Officer at Aerami Therapeutics, Inc. from 2013 to 2016, Vice President-Finance & Administration at Sangamo Therapeutics, Inc. from 2003 to 2013, Director-Finance & Administration at Calyx Therapeutics, Inc. from 2001 to 2003, Senior Vice President at Matrix Pharmaceutical, Inc. from 1995 to 2001, and Senior Staff Accountant at Ernst & Young LLP from 1993 to 1995.
Mr. Zante completed undergraduate studies at the University of California, Los Angeles.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2026 | 185’538 ( 0.16% ) | 6 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| VIKING THERAPEUTICS, INC. | Finanzdirektor/CFO | 04.01.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
Aerami Therapeutics, Inc.
Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled insulin products to treat diabetes patients | Finanzdirektor/CFO | 01.01.2016 |
| SANGAMO THERAPEUTICS, INC. | Verwaltungsdirektor | 01.06.2013 |
Calyx Therapeutics, Inc.
Calyx Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides therapies services for diabetes and inflammatory diseases | Finanzdirektor/CFO | - |
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Researches and develops pharmaceutical products | Corporate Officer/Principal | 01.12.2001 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Corporate Officer/Principal | 01.11.1995 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 7 |
|---|---|
Matrix Pharmaceutical, Inc.
Matrix Pharmaceutical, Inc. Medical SpecialtiesHealth Technology Researches and develops pharmaceutical products | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calyx Therapeutics, Inc.
Calyx Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides therapies services for diabetes and inflammatory diseases | Health Services |
Aerami Therapeutics, Inc.
Aerami Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled insulin products to treat diabetes patients | Health Technology |
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for metabolic and endocrine disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen